BioDecade Selected Biotech Links

Nature Biotechnology: CD20 blockers eye crowded rheumatology

Nature Biotechnology:

Can complexity be

commercialized?

Nature Biotechnology:

MicroRNA gets down to

Nature Biotechnology:

Profile: Julian Davies

Nature Medicine: Clinical Trials Going to the Dogs

Journal of the National Cancer Institute: Epigenetic Cancer Therapy Makes

Decision Resources

Oncology Pipelines: Is the Future Targeted

Decision Resources: Lessons Learned from the Current Crop of

Decision Resources: Dealmaking and Financing: Buying In Innovation

Nature Medicine

Revolt in Bethesda

Nature Publishing Group: Momentous patent case

Nature Publishing Group:

Early-stage exits:

Sometimes, less is

Nature Publishing Group:

IBM opens the IP vaults

Nature Biotechnology:

Big pharma wants you

Nature Publishing Group: Canada's alternative biotech scene is an island

Nature Publishing Group: Biotech's challenge in Africa

Nature Publishing Group: Investors and the precautionary principle

Nature Publishing Group: Mad about medtech

Selected Biotech Links

© 2008 BioDecade and George S. Mack. All Rights Reserved

Outside Resource
Links